Mendel Money Management Purchases Shares of 3,005 Illumina, Inc. (NASDAQ:ILMN)

Mendel Money Management bought a new position in Illumina, Inc. (NASDAQ:ILMN) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor bought 3,005 shares of the life sciences company’s stock, valued at approximately $402,000.

Other institutional investors have also recently made changes to their positions in the company. WCM Investment Management LLC lifted its stake in Illumina by 26.6% in the 4th quarter. WCM Investment Management LLC now owns 4,129,855 shares of the life sciences company’s stock worth $551,625,000 after purchasing an additional 867,673 shares in the last quarter. ARK Investment Management LLC purchased a new stake in Illumina during the 4th quarter valued at $91,714,000. Janus Henderson Group PLC boosted its stake in shares of Illumina by 40.5% during the 3rd quarter. Janus Henderson Group PLC now owns 2,168,057 shares of the life sciences company’s stock worth $282,735,000 after purchasing an additional 625,245 shares during the period. Nikko Asset Management Americas Inc. bought a new position in Illumina in the 4th quarter valued at $65,813,000. Finally, Sumitomo Mitsui Trust Group Inc. increased its position in shares of Illumina by 116.9% during the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 865,546 shares of the life sciences company’s stock worth $115,663,000 after acquiring an additional 466,519 shares during the period. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages recently commented on ILMN. Canaccord Genuity Group reduced their price objective on shares of Illumina from $135.00 to $115.00 and set a “hold” rating for the company in a research note on Tuesday, March 11th. Hsbc Global Res downgraded Illumina from a “strong-buy” rating to a “hold” rating in a research report on Friday, February 28th. Guggenheim decreased their price objective on shares of Illumina from $170.00 to $150.00 and set a “buy” rating for the company in a research note on Friday, February 7th. Citigroup dropped their target price on Illumina from $130.00 to $90.00 and set a “neutral” rating on the stock in a report on Tuesday, March 4th. Finally, TD Cowen cut shares of Illumina from a “buy” rating to a “hold” rating and cut their price objective for the company from $177.00 to $140.00 in a report on Friday, February 7th. One analyst has rated the stock with a sell rating, ten have given a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Illumina has a consensus rating of “Moderate Buy” and a consensus price target of $140.90.

Illumina Trading Down 0.6 %

NASDAQ ILMN opened at $87.53 on Wednesday. The firm’s 50-day moving average is $106.10 and its two-hundred day moving average is $127.71. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.77 and a quick ratio of 1.42. Illumina, Inc. has a 12 month low of $80.18 and a 12 month high of $156.66. The stock has a market capitalization of $13.86 billion, a P/E ratio of -11.40, a PEG ratio of 1.60 and a beta of 1.17.

Illumina (NASDAQ:ILMN) last announced its earnings results on Thursday, February 6th. The life sciences company reported $0.86 EPS for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. On average, sell-side analysts anticipate that Illumina, Inc. will post 4.51 earnings per share for the current year.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.